ReviewScience in One Health2026
One Health antimicrobial resistance modelling: from science to policy.
Review in Science in One Health, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
Abstract
Modern human and veterinary medical interventions to combat infectious diseases depend on the continued efficacy of antimicrobial drugs. Antimicrobial resistance (AMR) is the quintessential One Health challenge threatening human and animal health and welfare and has environmental effects on ecological communities in soil and water. Policy guidance on AMR needs to anticipate the likely outcomes of different interventions and courses of action. For that, transdisciplinary collaboration to understand the development, spread, and impacts of AMR is crucial. We report the outcomes of an international workshop that explored the challenges and opportunities for modelling AMR across One Health settings. They include the disparity of data quality and availability, the broader knowledge gaps in key areas such as the relationship between antimicrobial use (AMU) and AMR, and the difficulty of defining AMR as a single outcome given its heterogeneity. Differences between microbial species, resistance genes, environments (i.e., terrestrial vs. aquatic) and practical settings (e.g., human clinical vs. veterinary, or individual vs. population) complicate the generalizability of model applications. However, synoptic AMR metrics are necessary to cut through the complexity for policymaking. We discuss the status of AMR modelling with respect to a hierarchy of modelling evidence for decision-making. Finally, we consider learnings from modelling other wicked environmental challenges to develop a pragmatic approach to inform policy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.